Our lab investigates the mechanisms responsible for brain damage in neuroinflammatory conditions through a combination of biological fluid characterization and neuroimaging studies. We are particularly interested in the study of cerebrospinal fluid as a window into the mechanisms of disease progression, with the goal of identifying markers for its early detection and monitoring in the clinical setting, and reveal pathways for the development of therapies targeting progressive disease. We also investigate the mechanisms underpinning the clinical heterogeneity of MOG-antibody associated disease (MOGAD), and their implications for the long-term outcome of people living with this condition.

1. Fadda G., Flanagan E. P., Cacciaguerra L., Jitprapaikulsan J., Solla P., Zara P., Sechi E. (2022), Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD, Frontiers in Neurology, 13:1011579
PMID: 36419536, DOI: 10.3389/fneur.2022.1011579

2. Magliozzi R., Fadda G., Brown R., Bar-Or A., Howell O.W., Hamentener S., Marastoni D., Poli A., Nicholas R., Calabrese M., Monaco S., Reynolds R. (2022), Ependymal-in gradient of thalamic damage in progressive multiple sclerosis, Annals of Neurology
PMID: 35748636; DOI: 10.1002/ana.26448

3. Fadda G., Waters P., Woodhall M., Brown R.A., O’Mahony J, Castro D, Longoni G., Yeh E.A., Marrie R.A., Arnold D.L., Banwell B., Bar-Or A. (2022), Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria, Multiple Sclerosis Journal, 13524585221093789
PMID: 35581944; DOI: 10.1177/13524585221093789

4. Fadda G., Alves C.A., O'Mahony J., Castro D. A., Yeh E.A., Marrie R.A., Arnold D.L., Waters P., Bar-Or A., Vossough A., Banwell B. (2021), Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes, JAMA network open 4 (10), e2128871-e2128871
PMID: 34643718, DOI: 10.1001/jamanetworkopen.2021.28871

5. Fadda G., Armangue T., Hacohen Y., Chitnis T., Banwell B. (2021), Pediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging and biological considerations for diagnosis and care, The Lancet Neurology 20 (2), 136-149
PMID: 33484648, DOI: 10.1016/S1474-4422(20)30432-4

6. Waters P.*, Fadda G.* (*equal contribution), Woodhall M., Irani S., O’Mahony J., Brown R.A., Castro D., Longoni G., Yeh E. A., Marrie R.A., Arnold D., Banwell B., Bar-Or A. (2020), on behalf of the Canadian Pediatric Demyelinating Disease Network, “Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes”, JAMA neurology 77 (1), 82-93
PMID: 31545352, DOI: 10.1001/jamaneurol.2019.2940

7. Fadda G., Brown R.A., Magliozzi R., Shinoara R., Aubert-Broche B., O’Mahoney J., Banwell B., Marrie R.A., Yeh E.A., Collins D.L., Arnold D.L., Bar-Or A. (2019), on behalf of the Canadian Pediatric Demyelinating Disease Network, “A ‘surface-in’ gradient of damage evolves in pediatric multiple sclerosis”, Annals of neurology 85 (3), 340-351
PMID: 30719730, DOI: 10.1002/ana.25429

8. Fadda G, Brown RA, Longoni G, Castro D, O’Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B, on behalf of the Canadian Pediatric Demyelinating Disease Network (2018), “MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study”, The Lancet Child & Adolescent Health 2 (3), 191-204
PMID: 30169254, DOI: 10.1016/S2352-4642(18)30026-9